Literature DB >> 19614708

Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.

A I Scher1, R B Lipton, W F Stewart, M Bigal.   

Abstract

Though symptomatic medication overuse is believed to play a role in progression from episodic headaches (EH) to chronic daily headaches (CDH), population-based data on this topic are limited. Our objective was to describe patterns of medication use among CDH and EH sufferers in a general population sample. We compared medications used to treat headache in CDH cases and EH controls identified from a large population-based computer-assisted telephone interview survey. CDH began within 5 years of the computer-assisted telephone interview. Questions on medication use focused on treatment prior to the onset of CDH for cases and on an equivalent period in the past for controls. We asked about the likelihood of treating, time waiting to treat, number of different medications used, first, second and third most frequently used headache pain medication, and total treatment days. Questions were also asked about the use of medication for non-headache pain. Current treatment patterns and past treatment patterns were assessed. Likelihood of use of specific medications was compared between CDH cases and EH controls after adjusting for age, sex, primary headache type and number of medications taken to treat pain. Our sample consists of 206 CDH cases and 507 EH controls. CDH subjects were more likely than EH controls to use over-the-counter/caffeine combination products, triptans, opioid compounds and 'other' prescription pain medications. Use of aspirin was protective. After adjustment, aspirin and ibuprofen were (negatively) associated with CDH [OR = 0.5 (0.3-0.9), OR = 0.7 (0.5-1.0)] and opioids remained positively associated with CDH [OR = 2.3 (1.3-3.9)]. For past use, CDH was positively associated with over-the-counter/caffeine combination products and opioid compounds and was negatively associated with use of aspirin. Only ibuprofen remained (negatively) associated with CDH after adjustment [OR = 0.6 (0.4-0.9)]. After adjusting for demographic factors, primary headache type and number of medications taken, CDH sufferers are more likely to use opioid-combination analgesics, and less likely to use aspirin or ibuprofen, than EH sufferers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19614708     DOI: 10.1111/j.1468-2982.2009.01913.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  35 in total

Review 1.  Opioid-induced central immune signaling: implications for opioid analgesia.

Authors:  Peter M Grace; Steven F Maier; Linda R Watkins
Journal:  Headache       Date:  2015-03-31       Impact factor: 5.887

Review 2.  Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

Authors:  Andreas Straube; Bernhard Aicher; Bernd L Fiebich; Gunther Haag
Journal:  BMC Neurol       Date:  2011-03-31       Impact factor: 2.474

3.  Trends in the ambulatory management of headache: analysis of NAMCS and NHAMCS data 1999-2010.

Authors:  John N Mafi; Samuel T Edwards; Nigel P Pedersen; Roger B Davis; Ellen P McCarthy; Bruce E Landon
Journal:  J Gen Intern Med       Date:  2015-01-08       Impact factor: 5.128

Review 4.  Medication-overuse headache: a perspective review.

Authors:  Maria Lurenda Westergaard; Signe Bruun Munksgaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  Ther Adv Drug Saf       Date:  2016-06-30

Review 5.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

6.  A new mutation in GFAP widens the spectrum of Alexander disease.

Authors:  Michael Brenner; Albee Messing
Journal:  Eur J Hum Genet       Date:  2014-06-25       Impact factor: 4.246

7.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

8.  [Preventing and treating medication overuse headache].

Authors:  K B Alstadhaug; H K Ofte; E S Kristoffersen
Journal:  Schmerz       Date:  2018-06       Impact factor: 1.107

9.  Chronic morphine increases Fos-positive neurons after concurrent cornea and tail stimulation.

Authors:  Ashlee Robbins; David Schmitt; Barbara J Winterson; Ian D Meng
Journal:  Headache       Date:  2011-09-19       Impact factor: 5.887

10.  Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: Implications for extracranial origin of headache.

Authors:  Carlton J Perry; Pamela Blake; Catherine Buettner; Efstathios Papavassiliou; Aaron J Schain; Manoj K Bhasin; Rami Burstein
Journal:  Ann Neurol       Date:  2016-05-05       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.